S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:ACRX

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

$0.23
0.00 (0.00%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.22
$0.23
50-Day Range
$0.18
$0.35
52-Week Range
$0.16
$1.25
Volume
713,903 shs
Average Volume
1.74 million shs
Market Capitalization
$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,080.5% Upside
$5.00 Price Target
Short Interest
Bearish
7.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.49mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$10,208 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.23) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

503rd out of 1,283 stocks

Pharmaceutical Preparations Industry

240th out of 615 stocks

ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

AcelRx Pharmaceuticals Stock Performance

Shares of NASDAQ:ACRX remained flat at $0.23 during mid-day trading on Friday. 713,903 shares of the company were exchanged, compared to its average volume of 1,740,321. AcelRx Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $1.25. The company has a market cap of $33.73 million, a price-to-earnings ratio of -0.85 and a beta of 0.44. The company has a 50-day moving average price of $0.23 and a 200-day moving average price of $0.29.

AcelRx Pharmaceuticals (NASDAQ:ACRX - Get Rating) last issued its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.44 million during the quarter, compared to analysts' expectations of $0.50 million. During the same period in the prior year, the business earned ($0.08) EPS. On average, research analysts predict that AcelRx Pharmaceuticals will post -0.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st. They set a "sell" rating on the stock.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

Why AcelRx Pharma Shares Are Trading Higher Today?
AcelRx stock falls 18% following Q4 results
AcelRx Pharmaceuticals Q4 2021 Earnings Preview
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings
5/16/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+2,080.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-35,100,000.00
Net Margins
-1,266.53%
Pretax Margin
-1,266.35%

Debt

Sales & Book Value

Annual Sales
$2.82 million
Book Value
($0.30) per share

Miscellaneous

Free Float
139,023,000
Market Cap
$33.73 million
Optionable
Optionable
Beta
0.44

Key Executives

  • Mr. Vincent J. Angotti (Age 54)
    CEO & Director
    Comp: $915.29k
  • Dr. Pamela Pierce Palmer M.D. (Age 59)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $682k
  • Mr. Raffi Mark Asadorian (Age 53)
    Chief Financial Officer
    Comp: $623.1k
  • Mr. Lawrence G. Hamel (Age 70)
    Consultant
  • Mr. Anil N. Dasu (Age 59)
    Chief Engineering Officer













ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AcelRx Pharmaceuticals stock.
View analyst ratings for AcelRx Pharmaceuticals
or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price forecast for 2022?

2 equities research analysts have issued 1 year price targets for AcelRx Pharmaceuticals' stock. Their ACRX stock forecasts range from $5.00 to $5.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 2,080.5% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has AcelRx Pharmaceuticals' stock performed in 2022?

AcelRx Pharmaceuticals' stock was trading at $0.56 at the beginning of the year. Since then, ACRX shares have decreased by 59.1% and is now trading at $0.2293.
View the best growth stocks for 2022 here
.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 11,210,000 shares, an increase of 81.4% from the June 30th total of 6,180,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the short-interest ratio is presently 5.4 days.
View AcelRx Pharmaceuticals' Short Interest
.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for AcelRx Pharmaceuticals
.

How can I listen to AcelRx Pharmaceuticals' earnings call?

AcelRx Pharmaceuticals will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Monday, May, 16th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The specialty pharmaceutical company earned $0.44 million during the quarter, compared to analysts' expectations of $0.50 million. During the same period in the prior year, the company posted ($0.08) EPS.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Values First Advisors Inc. (0.52%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.23.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $33.73 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does AcelRx Pharmaceuticals have?

AcelRx Pharmaceuticals employs 43 workers across the globe.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for AcelRx Pharmaceuticals is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.